[{"id":"a6b37777-854d-4900-9204-6341103aad43","acronym":"","url":"https://clinicaltrials.gov/study/NCT03776812","created_at":"2021-01-18T18:40:59.338Z","updated_at":"2024-07-02T16:36:08.046Z","phase":"Phase 2","brief_title":"Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03776812","lead_sponsor":"Corcept Therapeutics","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Lifyorli (relacorilant)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 01/28/2019","start_date":" 01/28/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2022-06-30"}]